Oncology Phase 2 Deal Benchmarks — Japan (2026)
Median upfront of $21M with total deal values reaching $181M in Japan territory.
Median Upfront
$21M
Total Deal Value
$134M
Royalty Range
3.9%–8.9%
Territory Multiplier
0.09x
Understanding Oncology Deal Benchmarks at Phase 2
Phase 2 Oncology licensing deals in Japan territory command a median upfront payment of $21M, with values ranging from $12M at the low end to $30M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the oncology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $87M to $181M, with a median of $134M. Royalty rates for oncology assets at this stage typically fall between 3.9% and 8.9% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Japan territory applies a 0.09x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating japan rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $12M | $21M | $30M |
| Total Deal Value | $87M | $134M | $181M |
| Royalty Rate | 3.9% | — | 8.9% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2024 | Ono Pharmaceutical | BMS | $0M | $1.2B | licensing |
| 2023 | Astellas Pharma | Seagen | $0M | $800M | codevelopment |
| 2023 | Daiichi Sankyo | N/A (Japan rights retained) | $0M | $2.1B | codevelopment |
| 2017 | Eagle Pharmaceuticals | SymBio Pharmaceuticals | $13M | $18M | reformulation |
See All Comparable Deals
View 4 comparable Oncology transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Phase 2 Oncology deals in Japan territory?
How does Japan territory affect Oncology deal value?
What royalty rates are typical for Phase 2 Oncology licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$6M upfront
Oncology · Preclinical · Japan
$12M upfront
Oncology · Phase 1 · Japan
$55M upfront
Oncology · Phase 3 · Japan
$85M upfront
Oncology · Approved · Japan
$25M upfront
Neurology/CNS · Phase 2 · Japan
$49M upfront
Immunology · Phase 2 · Japan
$61M upfront
Metabolic/Obesity · Phase 2 · Japan
$235M upfront
Oncology · Phase 2 · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Oncology Phase 2 Deal Benchmarks — Japan (2026). Retrieved from https://solidus.ambrosiaventures.co/data/oncology-phase-2-deals-japan
<a href="https://solidus.ambrosiaventures.co/data/oncology-phase-2-deals-japan">Oncology Phase 2 Deal Benchmarks — Japan (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=oncology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.